---
title: "BUZZ-Street View: J&J's macro troubles to pass, brokerages say"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301842392.md"
datetime: "2026-10-14T12:29:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301842392.md)
  - [en](https://longbridge.com/en/news/301842392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301842392.md)
generator: "portal-rs"
---

# BUZZ-Street View: J&J's macro troubles to pass, brokerages say

Johnson & Johnson (JNJ.N) on Tuesday missed Wall Street expectations for sales at its medical devices business, hurt by geopolitical issues including the Middle East conflict

On average, 26 analysts rate stock “buy”; their median PT is $280 - data compiled by LSEG

### FOCUS ON 2027

Raymond James (“outperform,” PT: $278) says “the international softness is transient and expect ‘27 estimates to re-base lower (closer to our estimates), to a healthier, more beatable level”

J.P. Morgan (“neutral,” PT: $285) says macro headwinds including pricing pressure in China and slowdown in Middle East to ease through 2027

RBC Capital Markets (“outperform,” PT: $280) says stock sell-off post results “sets a negative tone for the broader Pharma sector and underscores the heightened volatility in today’s market”

BofA Global Research (“neutral,” PO: $275) sees JNJ as “solid pharma growth stock” but stock’s premium valuation and modest consensus upside creates balanced risk-reward

Citigroup (“buy,” PT: $303) says broader Medtech market remains healthy, but co’s challenge is to better convert steady demand into consistent results

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)

## Related News & Research

- [J&J beats earnings estimates; Middle East conflict weighs on medical device sales](https://longbridge.com/en/news/301694227.md)
- [J&J falls premarket despite raised earnings guidance](https://longbridge.com/en/news/301699805.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Gilead To Hand $45,000,000 to Texas After Allegedly Using “Free Nurses” as Kickbacks To Boost Medicaid Prescriptions](https://longbridge.com/en/news/302963005.md)
- [Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis](https://longbridge.com/en/news/301420344.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**